BONAVENTURA, ALDO
 Distribuzione geografica
Continente #
EU - Europa 10.867
Totale 10.867
Nazione #
IT - Italia 10.867
Totale 10.867
Città #
Genova 8.100
Genoa 1.026
Rapallo 1.018
Vado Ligure 697
Bordighera 26
Totale 10.867
Nome #
Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin. 181
Early reduction of matrix metalloproteinase-8 serum levels is associated with leptin drop and predicts diabetes remission after bariatric surgery 176
Alamandine abrogates neutrophil degranulation in atherosclerotic mice 174
C-Reactive Protein Levels at the Midpregnancy Can Predict Gestational Complications 163
Anemia Due to Inflammation in an Anti-Coagulated Patient with Blue Rubber Bleb Nevus Syndrome 154
Levels of serum uric acid at admission for hypoglycaemia predict 1-year mortality 151
Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients 150
Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents 150
High baseline C-reactive protein levels predict partial type 2 diabetes mellitus remission after biliopancreatic diversion 145
Coronary stenting: A matter of revascularization 139
Sepsis by Pasteurella multocida in an Elderly Immunocompetent Patient after a Cat Bite 137
Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke 135
Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis 134
Pre-surgery age-adjusted Charlson Comorbidity Index is associated with worse outcomes in acute cholecystitis 134
Sofosbuvir/velpatasvir: A promising combination 133
The Role of Inflammation in Cardiovascular Outcome 130
Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis 129
Serum adiponectin levels predict acute coronary syndrome (ACS) in patients with severe carotid stenosis 126
High serum levels of C-reactive protein (CRP) predict beneficial decrease of visceral fat in obese females after sleeve gastrectomy 125
Update on the effects of treatment with recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke 124
Plasma palmitoylethanolamide (PEA) as a potential biomarker for impaired coronary function 123
Inflammation and pericarditis: Are neutrophils actors behind the scenes? 123
The Pathophysiological Role of Neutrophil Extracellular Traps in Inflammatory Diseases 122
Comment on "Diabetes remission after bariatric surgery is characterized by high glycemic variability and high oxidative stress" 121
The Role of Adipocytokines in Coronary Atherosclerosis 120
Impact of Endocrine Disorders on Vasculature 119
Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis 119
Aspirin in primary prevention for patients with diabetes: still a matter of debate 117
Update on strategies limiting iatrogenic hypoglycemia 116
A translational evidence for cholesteryl ester transfer protein (CETP) modulation by glucocorticoids: a time for reflection 116
Serum lipoprotein (a) predicts acute coronary syndromes in patients with severe carotid stenosis 116
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 115
The need of identifying circulating biomarkers of coronary dysfunction 114
Comment on "Characterization of circulating leukocytes and correlation of leukocyte subsets with metabolic parameters 1 and 5 years after diabetes diagnosis" 113
Baseline neutrophil-to-lymphocyte ratio is associated with long-term T2D remission after metabolic surgery 113
Baseline hs-CRP predicts hypertension remission in metabolic syndrome 112
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: Evaluation with euglycemic clamp and oral fat load 111
Adipocytokine levels in obese and non-obese subjects: An observational study 110
Obesity phenotypes and their paradoxical association with cardiovascular diseases 109
Resistin exerts a beneficial role in atherosclerotic plaque inflammation by inhibiting neutrophil migration 109
The pathophysiological role of cholecystokinin-1 receptor in mouse cholelithogenesis 108
Platelet-to-lymphocyte ratio at the time of carotid endarterectomy is associated with acute coronary syndrome occurrence 108
Comment on Hypoglycemia and hyperglycemia are risk factors for falls in the hospital population by Berra et al 107
The STOP DIABETES study: when prevention works 106
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies 105
CCL23 is a promising biomarker of injury in patients with ischemic stroke 104
Diabetes and Vascular Disease: is it all about Glycemia? 104
Reply to “Osteopontin inhibits macrophage cholesterol efflux via NF-κB/ABCA1 pathway” 103
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients 102
Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review 102
Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases 101
Biophysical aspects and novel treatments of atrial fibrillation 101
THE EFFECTS OF DIFFERENT DIALYSIS TREATMENTS ON GLYCEMIC EXCURSIONS AND INFLAMMATION IN PATIENTS WITH END-STAGE RENAL DISEASE WITH AND WITHOUT TYPE 2 DIABETES MELLITUS 100
Monocyte count at onset predicts post-stroke outcomes during a 90-day follow up 97
Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases 97
Impact of endocrine disorders on blood pressure. 97
Comment on G. Veronese and colleagues. Costs associated with emergency care and hospitalization for severe hypoglycemia 96
Targeting Inflammation in Primary Cardiovascular Prevention 96
Serum levels of osteopontin predict diabetes remission after bariatric surgery 95
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients 94
Impact of Red Wine Consumption on Cardiovascular Health 94
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 93
Alamandine inhibits neutrophil-mediated activities in mouse atherosclerosis. 92
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients 92
T-cells in myocardial infarction: Culprit instigators or mere effectors? 92
Reply to "PCSK9: Entering a new era of cardiovascular risk prediction" 92
Effects of berberine on lipid profile in subjects with low cardiovascular risk 91
Inflammasome Formation in Granulomas in Cardiac Sarcoidosis 89
Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to reduce cardiovascular inflammation and outcomes 88
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients 88
Low serum C-reactive protein levels predict 90-day mortality in hypoglycaemic patients 85
Cellular recruitment in myocardial ischemia/reperfusion injury 85
The NLRP3 inflammasome in acute myocardial infarction 85
Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: A 2-year study evaluation 82
The role of resistin and myeloperoxidase in severe sepsis and septic shock: results from the ALBIOS trial 81
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment 80
In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure? 78
Antiapolipoprotein A-1 Autoantibody Positivity Is Associated with Threatened Abortion 78
Effects of canrenone in patients with metabolic syndrome 77
Novel findings in neutrophil biology and their impact on cardiovascular disease 77
MicroRNA-122 in heart failure with reduced ejection fraction: Epiphenomenon or causal? 74
Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists 73
Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients 72
Leptin/adiponectin ratio as a potential predictor of clinical outcome after ischemic stroke. 70
Comparison of vildagliptin and glimepiride: Effects on glycaemic control, fat tolerance and inflammatory markers in people with Type 2 diabetes 70
Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction 69
Serum osteopontin as a potential predictor of post-stroke neurological outcome. 68
Troponin elevation does not always mean cardiac ischemia. 67
Neutrophil Extracellular Traps and Cardiovascular Diseases: An Update 67
A randomized, placebo-controlled study on the effects of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters 65
Drugs to Inhibit the NLRP3 Inflammasome: Not Always On Target 63
Early osteopontin levels predict mortality in patients with septic shock 63
Enalapril/lercanidipine combination on markers of cardiovascular risk: A randomized study 61
Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19) 60
Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients 59
The reduction of matrix metalloproteinase-8 serum levels after bariatric surgery is associated with leptin drop and predicts diabetes remission 59
PCSK9 is a promising prognostic marker in patients with advanced NSCLC 59
Neutrophil-Related Oxidants Drive Heart and Brain Remodeling After Ischemia/Reperfusion Injury 59
Serum levels of osteopontin predict atherosclerotic plaque rupture 58
Serum PCSK9 reduction after ischemic stroke predict worse outcome and higher MACEs occurrence. 57
Totale 10.243
Categoria #
all - tutte 39.695
article - articoli 38.880
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 639
Totale 79.214


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.217 0 0 0 0 348 497 658 367 408 484 314 141
2020/20211.582 126 151 197 213 83 73 63 151 118 174 98 135
2021/20221.476 52 50 90 190 32 138 40 351 149 146 60 178
2022/20231.241 142 89 12 117 178 193 2 106 223 5 150 24
2023/2024801 35 79 22 88 50 124 55 69 48 23 70 138
2024/2025784 119 193 82 136 254 0 0 0 0 0 0 0
Totale 11.435